Scholarlink

Purpose <p>Cushing’s syndrome (CS) is a rare condition marked by overt hypercortisolism, while mild autonomous cortisol secretion (MACS) refers to asymptomatic or subclinical cortisol excess, often associated with adrenal incidentalomas (AI). MACS is significantly more prevalent than CS, particularly in older populations. The 1&#xa0;mg overnight dexamethasone suppression test (F-1mgDST) is the main diagnostic tool, but the appropriateness of its current cut-off value of 1.8&#xa0;µg/dL is under debate.</p> Methods <p>This review briefly analyses existing literature to assess whether this threshold accurately identifies patients with cortisol-related comorbidities, especially in those with non-functioning AI (NFAI). We searched PubMed, Web of Science and Scopus between January 1990 and March 2025 using the following keywords: “adrenal incidentalomas, non-functioning adrenal incidentalomas, adrenal adenomas, non-functioning adrenal adenomas, subclinical hypercortisolism, mild hypercortisolism, less severe hypercortisolism, hidden hypercortisolism, mild autonomous cortisol secretion”.</p> Results <p>Evidence suggests that NFAI patients often present with metabolic, cardiovascular, bone and muscle alterations typical of cortisol excess, even with F-1mgDST values below 1.8&#xa0;µg/dL. Several studies propose that a lower threshold (around 1.2&#xa0;µg/dL) may better capture at-risk individuals, although this could reduce specificity and increase false positives.</p> Conclusions <p>The review highlights the need for more sensitive diagnostic criteria, possibly including biomarkers and pharmacological challenge tests. It also introduces the concept of a cortisol “milieu” in eucortisolemic individuals, suggesting that even normal-range cortisol activity and/or altered cortisol circadian rhythm may contribute to chronic conditions. In light of current evidence, closer monitoring of AI patients with F-1mgDST above 1.2&#xa0;µg/dL is recommended, pending validation from longitudinal and interventional studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lowering the dexamethasone suppression test cut-off: is it time yet?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月26日

查看全文
  • Vittoria Favero,
  • Cristina Eller-Vainicher,
  • Valentina Morelli,
  • Alfredo Scillitani,
  • Iacopo Chiodini

摘要

Purpose

Cushing’s syndrome (CS) is a rare condition marked by overt hypercortisolism, while mild autonomous cortisol secretion (MACS) refers to asymptomatic or subclinical cortisol excess, often associated with adrenal incidentalomas (AI). MACS is significantly more prevalent than CS, particularly in older populations. The 1 mg overnight dexamethasone suppression test (F-1mgDST) is the main diagnostic tool, but the appropriateness of its current cut-off value of 1.8 µg/dL is under debate.

Methods

This review briefly analyses existing literature to assess whether this threshold accurately identifies patients with cortisol-related comorbidities, especially in those with non-functioning AI (NFAI). We searched PubMed, Web of Science and Scopus between January 1990 and March 2025 using the following keywords: “adrenal incidentalomas, non-functioning adrenal incidentalomas, adrenal adenomas, non-functioning adrenal adenomas, subclinical hypercortisolism, mild hypercortisolism, less severe hypercortisolism, hidden hypercortisolism, mild autonomous cortisol secretion”.

Results

Evidence suggests that NFAI patients often present with metabolic, cardiovascular, bone and muscle alterations typical of cortisol excess, even with F-1mgDST values below 1.8 µg/dL. Several studies propose that a lower threshold (around 1.2 µg/dL) may better capture at-risk individuals, although this could reduce specificity and increase false positives.

Conclusions

The review highlights the need for more sensitive diagnostic criteria, possibly including biomarkers and pharmacological challenge tests. It also introduces the concept of a cortisol “milieu” in eucortisolemic individuals, suggesting that even normal-range cortisol activity and/or altered cortisol circadian rhythm may contribute to chronic conditions. In light of current evidence, closer monitoring of AI patients with F-1mgDST above 1.2 µg/dL is recommended, pending validation from longitudinal and interventional studies.